4009. The Patient Journey – From Hospital, to Home, to Heart Recovery
Industry-Expert Theater 2, #2455
Sponsored by Abiomed

• Underdiagnosis of CAD and CGS
• Patient Journey: Referral for PCI, transfer for CGS: CCL, ICU, OR
• Case based examples on CGS escalation, RHF support RP flex
• Difference between HF and AMI CGS

Speakers:
Ashley Bock, MD
Advanced Heart Failure Specialist Director of LVAD Program

Ann Gage, MD
Interventional Cardiologist and Cardiac Critical Care

Duck Nguyen, MD
Cardiothoracic Surgeon Director of Mechanical Circulatory Support

4001. Personalizing Patient Care Along the Heart Failure Journey
Industry-Expert Theater 1, #1957
Sponsored by Abbott

Heart failure is a complex and progressive disease, so it is important to have a multi-step management plan for these patients. In this program, experts will discuss Abbott's unique product portfolio that provides for lifetime management of Heart Failure. Featured in this discussion will be MitraClip™ Therapy and the CardioMEMS™ HF System, including recent studies that showed how the CardioMEMS™ HF System was able to measure the hemodynamic impact in patients that received TEER therapy.

Speakers:
Matthew J. Price, MD
Clinical Professor of Medicine
Director, Cardiac Catheterization Laboratory
Division of Cardiovascular Diseases, Scripps Clinic

Ajay Srivastava, MD, FACC
Advanced Heart Failure and Transplant Cardiology
Division of Cardiovascular Diseases, Scripps Clinic

Shashank S. Desai, MD, MBA
Director, Inova Thoracic Transplant
Director, Strategy and Growth Inova Heart & Vascular Institute

4002. Elevated Lipoprotein(a): Raise Your Game and Lower Your (Risk) Score?
Industry-Expert Theater 1, #1957
Sponsored by Novartis Pharmaceuticals Corporation

A disease state (non-CME), interactive Expert Panel presentation and discussion on lipoprotein(a) – the expert panelists will share information and data on a number of clinically relevant topics and demonstrate why elevated Lp(a) is a risk enhancer for ASCVD.

Speakers:
Nathan D. Wong, PhD, MPH
Professor and Director
UCI Heart Disease Prevention Program
University of California, Irvine School of Medicine
Irvine, CA

Leslie J. Donato, PhD
Assistant Professor and Clinical Chemist
Department of Laboratory Medicine and Pathology
Mayo Clinic
Rochester, MN

Leslee J. Shaw, PhD, FACC
Professor
Department of Medicine (Cardiology), Population Health Science and Policy, and Obstetrics, Gynecology and Reproductive Science
Mount Sinai Icahn School of Medicine
New York, NY

Emily E. Brown, MGC, CGC
Genetic Counselor
Center for Inherited Heart Disease
The Johns Hopkins University School of Medicine
Baltimore, MD

Patient Perspective
Speaker: Maurice Williams, PhD, MPH
Medical Science Liaison,
Associate Director
IM US Medical Affairs
Novartis Pharmaceuticals Corporation
East Hanover, NJ

4010. Breaking the Cycle of Recurrent Pericarditis: A Targeted Approach For Pain Relief, Inflammation Resolution and Flare Prevention
Industry-Expert Theater 2, #2455
Sponsored by Kiniksa Pharmaceuticals

For many patients, single- or first-episode pericarditis is just the beginning of their journey. Up to 30% of patients with pericarditis will experience a recurrent episode within 18 months, despite treatment with traditional therapies. Managing recurrent pericarditis (RP) can be a challenge for clinicians because pericarditis and RP are distinctly different in pathology, duration of disease, and risk of both recurrence and complications. At this Industry Expert Theater, we will review the diagnosis of RP, the underlying interleukin-1 (IL-1) pathway that drives the repetitive cycle of recurrence, insights regarding RP disease duration, and a treatment option for RP.

Speaker:
Robert W. W. Biederman, MD, FACC, FAHA, FSGC, FASA, FSCMR
Professor of Medicine Allegheny General Hospital/Temple University College of Medicine
Adjunct Professor of Medicine Carnegie Mellon University, Department of Bioengineering
Systems Director, Cardiovascular Imaging Allegheny General Hospital/AHN
Professor, Department of Medicine Drexel University College of Medicine

4003. ACC Recommends Lower LDL-C Thresholds For ASCVD Patients at Risk For CV Events
Industry-Expert Theater 1, #1957
Sponsored by Amgen

In this presentation we will discuss the new recommendation from the 2022 ACC Consensus Pathway around a lower LDL-C threshold for patients with ASCVD at very high risk for CV Events.

Speaker:
Payal Kohli, MD, FACC

4011. Jardiance® (empagliflozin) Tablets: A Review of the Latest Data
Industry-Expert Theater 2, #2455
Sponsored by Boehringer Ingelheim Pharmaceuticals, Inc. and Lilly USA, LLC

This program will review recent clinical trial data for JARDIANCE. It will also provide information on JARDIANCE initiation and dosing, as well as guidance for monitoring patients on JARDIANCE. Attendees will have the opportunity to ask the faculty questions about the data presented.

Speakers:
Javed Butler, MD, MPH, MBA
President, Baylor Scott & White Research Institute
Senior Vice President, Baylor Scott & White Health Distinguished
Professor of Medicine, University of Mississippi Dallas, Texas

Seth J. Baum, MD, FACC, FACPM, FAHA, FNLA, FASPC
Chief Scientific Officer, Flourish Research
Clinical Affiliate Professor of Cardiology, Charles E. Schmidt College of Medicine, Florida Atlantic University

Daniel Bensimhon, MD
Medical Director, Advanced HF & Mechanical Circulatory Support Program at Cone Health
Greensboro, North Carolina

Karol E. Watson, MD, PhD
Professor of Medicine, Department of Cardiology, David Geffen School of Medicine University of California, Los Angeles

4004. Recognizing the Underrecognized: Transthyretin Cardiac Amyloidosis, a Potential Underlying Cause of Heart Failure
Industry-Expert Theater 1, #1957
Sponsored by Pfizer

Transthyretin amyloid cardiomyopathy (or ATTR-CM) is a serious, underrecognized and underdiagnosed cause of heart failure. Early recognition of clinical clues and accurate diagnosis are crucial to starting patients on the appropriate continuum of care. Join us to help raise awareness of the signs and symptoms of ATTR-CM, and the role of cardiac health professionals in suspecting, diagnosing and confirming ATTR-CM. The program will end with a review of the clinical data supporting an oral treatment option for patients with this progressive disease.

Speaker:
Barry Trachtenberg, MD, FACC
Co-Director, Bradley Z Naifeh Amyloidosis Program at Houston Methodist J.C. Walter Jr. Transplant Center
Affiliate, Houston Methodist DeBakey Heart and Vascular Center
Co-Chair of Heart Failure Section, Texas Chapter of American College of Cardiology
Houston, TX

4012. Is LEQVIO® (inclisiran) an Attractive Therapy? What Makes it Different?
Industry-Expert Theater 2, #2455
Sponsored by Novartis Pharmaceuticals Corporation

This program will discuss key aspects that make LEQVIO compelling and explore scenarios and considerations that make it well suited for patients with ASCVD with elevated LDL-C who may need something more, despite their best efforts with diet and maximally tolerated statin. Don't miss the deep dive into the mechanism of action, dosing schedule, administration, clinical efficacy, and safety data.

Speaker:
Jason Lecocq, MD, MBA
Senior Medical Director, Atherosclerosis
US Clinical Development & Medical Affairs
Cardiovascular & Metabolism, Novartis Pharmaceuticals Corporation

4005. A Focus on Lipoproteins: Understanding Established and Emerging Cardiovascular Risk Factors in Patients With ASCVD
Industry-Expert Theater 1, #1957
Sponsored by Amgen

Come join Dr. Baber and Dr. Taub as they discuss established and emerging cardiovascular risk factors in patients with ASCVD.

Usman Baber, MD, MS, FACC, FSCAI
Associate Professor of Medicine (Cardiology)
Director, Interventional Cardiology Fellowship and Cardiac Catheterization Laboratory
University of Oklahoma Health Sciences Center

Pam Taub, MD, FACC, FASPC
Professor of Medicine (Cardiology)
Founder and Director, Step Family Cardiac Wellness and Rehabilitation Center
University of California, San Diego

4013. A Next Step in LDL-C–Lowering Therapy: Oral Nonstatin Therapies
Industry-Expert Theater 2, #2455
Sponsored by Esperion Therapeutics, Inc.

The session will cover the following information:

• Atherosclerotic cardiovascular disease and lipid management
• Unique mechanism of action for two treatment options
• Efficacy data for two treatment options
• Safety data for two treatment options

Speaker:
Kausik Ray, BSc, MBChB, FRCP, FRCP, MD, MPhil, FACC, FESC, FAHA
Professor of Public Health and Honorary Consultant Cardiologist, President European Atherosclerosis Society, Imperial College London

4006. Left Atrial Appendage Closure For Stroke Risk Reduction: New Data, New Insights
Industry-Expert Theater 1, #1957
Sponsored by Boston Scientific

This session will cover:

• Evolution of LAAC: Where are we now?
• Anticoagulation and device-based therapies: stroke risk, bleed risk, and what matters to patients
• What will happen with LAAC over the next decade? A peek into the future

Speakers:
Vivek Reddy, MD
Christine Chung, MD
Sean Pokorney, MD, MBA
Payal Kohli, MD

4014. Transforming Hypertension Management With Ultrasound Renal Denervation
Industry-Expert Theater 2, #2455
Sponsored by ReCor Medical

Please join this program if you want to:

• Learn the latest clinical evidence and the unique benefits of Ultrasound Renal Denervation (uRDN) Therapy
• Understand perspectives on patient selection
• Learn how to establish interventional hypertension therapy

Speakers:
Daichi Shimbo, MD
Ajay Kirtane, MD
Michael Bloch, MD
Andrew Sharp, PhD

4007. Advances in Technology For Managing Patients Across the Spectrum of Acute Cardiac Care
Industry-Expert Theater 1, #1957
Sponsored by ZOLL

This session will cover:

• ZOLL Arrhythmia Management System (AMS) and the MAPS trial
• Using AMS and the LifeVest in Routine Practice
• Patient Management of Acute Cardiac Patients and screening for sleep apnea with WatchPA

Speakers:
Harish Manyam, MD
Chief of Cardiology, Erlanger Heart and Lung Institute Head of Electrophysiology Associate Professor of Medicine, University of Tennessee Chattanooga, TN

Josh Montgomery, PA

Katie Minor, NP

4015. Worsening Heart Failure in Patients With Symptomatic Chronic HFrEF: Will You Recognize the Early Downward Trajectory?
Industry-Expert Theater 2, #2455
Sponsored by Cytokinetics

During this presentation, we will review the downward trajectory of worsening heart failure in patients with symptomatic chronic HFrEF. We will discuss the burden of worsening heart failure and current treatment strategies. We will also explore the challenges posed by worsening signs or symptoms in high-risk patients, and share best practice considerations to identify early signs or symptoms.

Speakers:
Stephen J. Greene, MD, FACC, FHSA
Division of Cardiology, Duke University School of Medicine and Duke Clinical Research Institute

James Januzzi, MD, FACC, FESC
Hutter Family Professor of Medicine, Harvard Medical School; Cardiology Division, Massachusetts General Hospital; Director of Heart Failure and Biomarker Trials, Baim Institute for Clinical Research

Robert Mentz, MD, FHFSA, FACC
Chief, Heart Failure Section, Duke University Medical Center; Associate Program Director, Duke Cardiovascular Disease Fellowship; Editor-in-Chief, Journal of Cardiac Failure, Official Journal of the HFSA

4008. Addressing the Risk of Early Recurrent MI: The Evolving Role of HDL in the 90-Day Post-AMI High-Risk Period
Industry-Expert Theater 1, #1957
Sponsored by CSL Behring

Could cholesterol efflux have the potential to reduce the high risk of recurrent CV events in the 90-day window following an AMI? Join our expert faculty of Dr. Eliot Brinton and Dr. Nihar Desai for discussion on the potential link between cholesterol efflux and the clinical importance of the high‑risk 90-day period following an AMI. The session will highlight risk of early recurrence of cardiovascular events despite advances in SOC, as well as explore current understanding of cholesterol efflux to potentially improve CV outcomes. We look forward to welcoming you to a lively, informative and interactive discussion.

Speakers:
Eliot Brinton, MD
President Utah Lipid Center, USA

Nihar Desai, MD, MPH
Associate Professor, Yale School of Medicine,
Associate Chief of the Section of Cardiovascular Medicine, Yale New Haven Health System, USA

4016. Time For CHANGE: Rethinking Rhythm Control to Improve Outcomes in AF
Industry-Expert Theater 2, #2455
Sponsored by Sanofi

Now recognized as a chronic disease requiring an integrated, life-long management strategy, timely restoration and maintenance of sinus rhythm in atrial fibrillation (AF) is emerging as a key component in improving outcomes. Clinical trial data and real-world studies strengthen a growing body of evidence that suggests early rhythm control is associated with improved cardiovascular outcomes, better quality of life, and reduced hospitalization. Join our distinguished panel of experts as they discuss the latest data, updated guideline recommendations, and how new trials are addressing the question of early rhythm control and first-detected AF.

Speakers:
Pam Taub, MD, FACC, FASPC (Chair)
Director of Step Family Foundation
Cardiovascular Rehabilitation and Wellness Center
Professor of Medicine
UC San Diego Health System Division of Cardiovascular Medicine
San Diego, California

Jonathan Piccini, MD, MHS, FHRS
Associate Professor of Medicine
Director, Cardiac Electrophysiology
Duke University
Durham, North Carolina

Jagmeet P. Singh, MD, ScM, PhD
Professor of Medicine
Massachusetts General Hospital and Harvard Medical School
Boston, Massachusetts